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Abstract 
Objectives 
Fatigue is a prevalent and debilitating symptom, preceded by an acute infectious episode in 
some patients. This systematic review aimed to identify risk factors for the development of 
persistent fatigue after an acute infection, to develop an evidence-based working model of post-
infectious fatigue.  
Methods 
Electronic databases (Medline, PsycINFO and EMBASE) were searched, from inception to 
March 2016, for studies which investigated biopsychosocial risk factors of on-going fatigue 
after an acute infection. Inclusion criteria were: prospective design; biological, psychological 
or social risk factors; standardised measure of post-infectious fatigue (self-report scales or 
clinical diagnosis). Studies were excluded if the sample had a pre-existing medical condition, 
infection was conceptualised as ‘vaccination’ or they were intervention trials. A narrative 
synthesis was performed.  
Results 
Eighty-one full texts were screened, of which seventeen were included in the review. Over half 
included glandular fever populations. Other infections included dengue fever, ‘general’/’viral’ 
and Q-fever. Risk factors were summarised under biological, social, behavioural, cognitive and 
emotional subthemes. Patients’ cognitive and behavioural responses to the acute illness, and 
pre-infection or baseline distress and fatigue were the most consistent risk factors for post-
infectious fatigue.  
Conclusion 
An empirical summary model is provided, highlighting the risk factors most consistently 
associated with persistent fatigue. The components of the model, the possible interaction of 
risk factors and implications for understanding the fatigue trajectory and informing 
preventative treatments are discussed.  
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Introduction 
 
Fatigue is a commonly reported symptom. Every year 1.5% of the UK population 
present to the GP with tiredness or fatigue as a new symptom (Gallagher et al., 2004) and 
between 5-7% of people attending primary care present with a primary complaint of fatigue 
(Hamilton et al., 2010).  
Around half of people with tiredness/fatigue as a major or concurrent symptom recover 
within one year (Nijrolder et al., 2008a, Nijrolder et al., 2008b). However, for some, fatigue 
persists for over six months, which is then defined as chronic (O’Halloran et al., 2004, Centers 
for Disease Control and Prevention (CDC), 2012). If more stringent criteria are met, including 
fatigue that is disabling in nature, a diagnosis of chronic fatigue syndrome (CFS) may be made 
(Sharpe et al., 1991, NICE, 2007, CDC, 2012). A recent review suggests the prevalence of 
clinically assessed CFS is approximatley 0.76% of the population (Johnston et al., 2013).  
 A number of precipitants or triggers have been associated with chronic fatigue, but no 
clear cause has been found (Lorusso et al., 2009). One common precipitant is moderate to 
severe, infectious viral illness, including infectious mononucleosis (IM)/glandular fever, Ross-
River virus (RRV) and Coxiella burnetti (Q-fever) (Ayres et al., 1998, Kondo, 2006, Hickie et 
al., 2006). However, the majority of people experiencing these infections do recover, 
suggesting that acute infection may be a ‘necessary but insufficient cause’ (White, 2007; p4). 
Current guidelines advocate tiredness/fatigue management in primary care by identifying and 
addressing relatively broad ‘modifiable psychological, social, and general health factors’ 
(NICE, 2015). However, it is currently not known which specific factors should be targeted. 
Summarising the current evidence of modifiable risk factors which interact with infection to 
maintain or perpetuate post-infectious fatigue may provide clearer guidance for treatment.   
A review by Candy et al. (2002) investigated clinical and psychological variables 
associated with recovery after IM and found that poor physical functioning predicted prolonged 
ill health, whilst evidence for symptom-related and psychological risk factors (mood disorder 
and personality) was mixed. The review, however, focused exclusively on IM and a number of 
prospective infectious studies have been published since this date. Additionally, the outcome 
was broadly defined as ‘recovery’ rather than persistent fatigue, for example, absence of 
persistent symptoms and psychological well-being. This could account for some of the 
inconsistent findings reported. 
A more recent scoping review identified a large number of heterogeneous risk factors 
associated with the onset of CFS. These ranged from childhood trauma and mood disorder, to 
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family members with CFS and recent ingestion of raw milk (Hempel et al., 2008). This review 
only included studies measuring clinically defined CFS, potentially missing risk factors of 
more general, persistent fatigue. Additionally, the studies included did not necessarily focus on 
post-infectious fatigue and ‘did not appear to reveal risk factors that are evidently useful for 
clinicians’ by being potentially modifiable (Hempel et al., 2008, p924).  Although fatigue can 
be precipitated by a range of factors, post infectious chronic fatigue may provide a more 
homogenous group to study (Fukuda et al., 1994). Therefore, the primary aim of this systematic 
review was to identify biopsychosocial risk factors associated with persistent fatigue post-
infection across the fatigue trajectory, which are potentially modifiable. Unmodifiable 
demographic factors such as gender were beyond the scope of the review. The secondary aim 
was to summarise the empirical findings in a theoretical model to guide development of early 
interventions to treat post-infectious fatigue.   
 
Methods 
Search strategy 
 
The databases Medline, PsycINFO and EMBASE were searched from inception to 
March 2016. The search strategy combined MeSH terms and key-words relating to fatigue, 
predictive design and infection (see Appendix A for full search strategies). Relevant grey 
literature was identified by contacting experts in the field and searching OpenGrey. The 
reference lists and citations of included studies were also hand-searched.  
 
Study selection 
 
Table 1 provides the overview of inclusion and exclusion criteria for studies. KH 
screened titles and abstracts and two authors (KH, PR) screened full-texts. Any uncertainties 
about study inclusion were resolved with the wider research team.  
 
 
 
 
 
Table I 
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Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
Prospective study design  
 
Intervention trials. 
Patients who had experienced an acute 
(short-term, non-chronic) infection 
confirmed by a doctor or laboratory test.  
 
The patient sample had a pre-existing 
medical condition. 
Assessed the presence of fatigue at a stated 
follow-up time-point following the 
infectious episode. 
 
The patient sample was already chronically 
fatigued at baseline. 
Reported quantitative and empirical data 
investigating risk factors of fatigue. 
 
The infection was conceptualised as 
‘vaccination’. 
Measured fatigue outcome using a valid and 
reliable self-report tool or diagnosis by a 
medical professional according to 
international diagnostic guidelines (Fukuda 
et al., 1994, Sharpe et al., 1991) or 
professional clinical opinion at follow-up. 
 
 
Measured biological, psychological, social 
or emotional risk factors, either before the 
onset or at the time of acute infection (not 
demographics). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data Extraction 
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The following information was independently extracted by KH and PR; infection 
characteristics, sample demographic characteristics, study design, statistical methods, risk 
factors, fatigue measure and follow-up time-points, and the statistical outcomes. Where 
relevant analyses were missing authors were emailed to request statistical results but responses 
were not received (N=3). Both univariate and multivariate results were extracted, but univariate 
findings were prioritised during synthesis to enable comparability across studies where 
possible. 
 
Assessment of within study risk of bias and study quality 
  
The methodological quality and risk of bias of included studies was assessed using The 
Effective Public Health Practice Project Quality Assessment Tool (Armijo‐Olivo et al., 2012). 
The tool rates studies on selection bias, study design, confounding variables, blinding, data 
collection and degree of withdrawal. The tool was modified to better assess observational 
studies, based on other tools (Downs and Black, 1998, Wells et al., 2000) (see Appendix B). 
We explored whether quality assessment domains could account for heterogeneity in review 
findings, according to recommendations by Reeves et al. (2008). 
 
Methods of Analysis 
 
The wide range of risk factors and fatigue measurement methods ruled out a meta-
analysis. Therefore, narrative synthesis was used, identifying themes among risk factors (Popay 
et al., 2006).  
 To provide meaningful comparison, risk factor data were extracted in categories 
according to fatigue time scales and definitions. Current guidelines suggest categorising fatigue 
according to three time periods following acute infection; <=3 months, 4+ months, and 12+ 
months (NICE, 2015). Accordingly, we classified fatigue as i) sub-acute, ii) chronic and iii) 
long-term, respectively. Within the ‘chronic’ grouping a distinction was made between studies 
using diagnostic criteria (e.g. Oxford (Sharpe et al., 1991) and/or CDC criteria) to define ‘CFS’ 
and those measuring the presence of ‘chronic fatigue’ using self-report. 
The review was conducted in accordance with PRISMA guidelines (Moher et al., 2009). 
Results 
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Study Characteristics 
 
The search returned 1,850 citations, of which 78 full texts were retrieved after screening 
titles and abstracts. Three full texts were identified from other sources. Eighteen articles met 
inclusion criteria. Study characteristics, including fatigue measures/criteria used, are detailed 
in Appendix C. Acute infections included IM (N=9), Q-fever, Ross-River virus (or a 
combination of the three), dengue fever, viral meningitis and shiga toxin-producing Escherichia 
coli 0104 (STEC) infection. Three studies investigated populations with ‘general’ or ‘viral’ 
infections. A range of follow-up time-points were used but six months (chronic) was the most 
common (N=11). The number of participants ranged from 71 to 2327, and mean ages fell 
between 16.09 years and 48.50 years. 
 Three papers used the same cohort (Katz et al., 2009, Huang et al., 2010, Jason et al., 
2014). As each of these papers reported different risk factors all were included in this review. 
Two papers reported anxiety and depression in different analyses for the same cohort of IM 
patients (Moss-Morris & Spence, 2006, Moss Morris et al., 2011); only data from the 2011 
publication were included here and the 2006 publication was excluded. One study (Cope et al., 
1996) included participants recruited from a previous cohort (Cope et al., 1994), with the 
addition of a healthy control group. The two papers were considerably different though; Cope 
et al. (1994) included more participants, used a cohort design and focussed on chronic fatigue, 
whereas Cope et al. (1996) focused on CFS and included controls. Therefore, both were 
included. In total, 17 papers are included in this narrative synthesis (see Figure 1). 
 
Insert Figure 1 here 
 
Grouping of risk factors 
 
Significant risk factors were grouped under five component themes (biological, social, 
behavioural, cognitive and emotional), with sub-themes where applicable. These risks factors 
are summarised in Figure 2, with more details by theme and fatigue time-point (sub-acute, 
chronic and long-term) in tables 3-7 (Appendix D). Factors in bold in Figure 2 were the ones 
most consistently related to fatigue, either across time points and/or in multiple studies. Other 
variables were only associated with fatigue at certain time points. Variables found not to be 
risks for fatigue in any studies are listed in table 2 and, for the sake of brevity, are not included 
in the synthesis.  
9 
 
Insert Figure 2 here 
 
Table 8 (Appendix E) summarises the ratings for each study across the quality domains, 
with studies rated as weak, moderate or strong. Of the quality domains assessed, ratings 
between studies differed particularly for ‘confounders’, ‘data collection’ and ‘withdrawal’. 
Where there were discrepant findings across studies in relation to risk factors and fatigue 
outcomes, we explored whether study quality, sample characteristics or infection 
characteristics could account for these.  
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Table II 
 
Measured variables which were not shown to be significant predictors of fatigue at any time-point. 
 
Biological 
 
Social Behavioural Cognitive Emotional 
 
Haemotological and biochemical parameters 
Inflammatory markers 
White cell count (Seet et al., 2007) 
IL-6 levels and CRP levels (Kremers et al., 2014) 
Stress markers 
Cortisol - baseline AUC values,  
Cortisol - change in AUC (baseline to six  months) 
(Candy et al., 2003) 
General markers 
(Concentrations of…) haemoglobin, haematocrit, platelet, sodium, 
potassium, urea, creatinine 
(Seet et al., 2007) 
Liver (among other) functions 
(Concentrations of…) albumin, total bilirubin, alkaline transaminase, 
alkaline phosphatase, lactate dehydrogenase, prothrombin time, activated 
thromboplastin time  
(Seet et al., 2007) 
yGT at 1 month, Bilirubin at 1 month (White et al., 2001) 
Symptoms at time of infection 
Acute sickness (Hickie et al., 2006) 
Fever, Nausea, Poor appetite, Cough, Abdominal pain, Vomiting 
Diarrhoea, Headaches (Seet et al., 2007) 
Neurological symptoms, 4+ instances of diarrhoea on 3+ days 
Abdominal pain, Length of bloody diarrhoea, Fever 
(Löwe et al., 2014) 
Medication during acute phase 
Steriod therapy during acute phase (Katz et al., 2009) 
Medication (antibiotic prescription) (Cope et al., 1994) 
Previous symptoms 
Premorbid atopy (Petersen et al., 2006) 
Diarrhoea in past 4 months (Löwe et al., 2014) 
Comorbid syndromes 
Hemolytic uremic syndrome (Löwe et al., 2014) 
Atopy (White et al., 2001) 
Weight 
Weight at baseline, Weight change over six months 
(Schur et al., 2008) 
Doctor’s advice 
… to rest 
(Moss-Morris et al., 2011, Candy et al., 2003).  
… to avoid exercise 
… to take medication (e.g. paracetamol)  
(Moss-Morris et al., 2011) 
 
Sickness certificate in the year before IM 
(Petersen et al., 2006) 
 
Family influence 
Family stress at or prior to onset 
Family stress at or prior to onset continuing 
Family stress since mononucleosis 
Family stress since mono continuing 
(Jason et al., 2014) 
Family psychiatric history  
(Cope et al., 1996) 
Childhood experience of illness in family 
(Candy et al., 2003) 
Perceived social support 
(Löwe et al., 2014) 
Exercise 
Exercise power 
(White et al., 2001) 
Does regular sport 
(Candy et al., 2003) 
 
Physical activity 
Physical and sedentary 
activities pre-infection and at 
baseline: 20-Minute hard 
exercise, 20-Minute light 
exercise, 
television/video/computer, 
sleep, napping, other sedentary 
activity (Huang et al., 2010) 
Individual traits 
Self- rated extroversion 
Relative-rated extroversion 
(White et al., 2001) 
Pessimism 
Optimism 
(Löwe et al., 2014) 
 
Illness beliefs 
Believing fatigue had a 
physical cause at 
presentation 
(Wessely et al., 1995) 
General beliefs about 
viruses (combination of 
perception of personal 
vulnerability to viruses, 
attribution of ill health to 
viruses and general beliefs 
about prevention and 
treatability of viral illness)  
(Cope et al., 1994) 
 
Other 
Locus of control (internal 
versus external) 
(Hickie et al., 2006) 
Self-efficacy 
Fear of death  
(Löwe et al., 2014) 
Symptoms at time 
of infection 
Mood disturbance 
(Hickie et al., 
2006) 
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Biological factors 
 
Haemotological and biochemical parameters 
A large number of biological markers were assessed (see table 2 for non-significant 
biological risks), but only three appear to be significant risk factors. During infection, higher 
percentage of activated CD4 (helper) and CD8 (cytotoxic) t-cells (Candy et al., 2003) and 
aspartate transaminase concentration (a measure of liver inflammation) (White et al., 2001), 
were risk factors for sub-acute fatigue, although aspartate transaminase concentration was not 
significant in multivariate analyses (controlling for demographics, symptoms, laboratory and 
dengue severity covariates) in a less representative (hospital inpatient) dengue fever sample 
(Seet et al., 2007).  
Aspartate transaminase concentration was also a risk for more broadly defined chronic 
fatigue but not CFS (White et al., 2001). Activated CD4 and CD8 percentages were not risk 
factors for chronic fatigue or CFS (Candy et al., 2003). 
 
Individual symptoms 
A wide range of symptoms reported at the time of infection were investigated as risk 
factors for fatigue. Fatigue reported at the time of acute infection was a risk factor for sub-acute 
fatigue in an IM (White et al., 2001) and a combined IM, Q-fever, RRV sample (Hickie et al., 
2006), but not in a dengue fever, inpatient sample (Seet et al., 2007). Other symptoms shown 
to be risks for sub-acute fatigue included lymphadenopathy (White et al., 2001), irritability, 
musculoskeletal pain, neurocognitive disturbance (Hickie et al., 2006), and presence of chills 
(Seet et al., 2007). A methodologically weaker study broadly measuring fatigue ‘in the year 
after onset’, reported lymphadenopathy was not associated with sub-acute fatigue (Petersen et 
al., 2006). 
Of these symptoms, fatigue and musculoskeletal pain remained significant risk factors 
for chronic fatigue (White et al., 2001) and CFS (Cope et al., 1996, Hickie et al., 2006, Huang 
et al., 2010). Autonomic symptoms were also a risk factor for CFS (Jason et al., 2014). 
In the only study to assess symptoms in relation to long-term fatigue only fatigue during 
infection was a significant risk (Hickie et al., 2006). 
 
 
 
Severity of acute symptoms 
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 Self-reported severity of general somatic symptoms was a risk factor for sub-acute 
fatigue in an IM sample (Candy et al., 2003) but objectively rated dengue fever severity was 
not (Seet et al., 2007). 
Self-reported severity of symptoms was not associated with chronic fatigue (Wessely 
et al., 1995, Candy et al., 2003), and neither was duration of inpatient care for STEC infection 
(Löwe et al., 2014). However, treatment in intensive care for STEC infection was associated 
with chronic fatigue (Löwe et al., 2014).  
 Self-reported severity of symptoms was associated with long-term fatigue in the only 
study to assess this time-point (Candy et al., 2003).  
 
Number of acute symptoms 
Three studies investigated overall number of self-reported symptoms (Wessely et al., 
1995, Candy et al., 2003, Moss-Morris et al., 2011). Number of general somatic symptoms was 
a risk factor for sub-acute fatigue in both IM studies to measure this (Candy et al., 2003, Moss-
Morris et al., 2011). However, the number of IM-specific symptoms was not significantly 
associated with sub-acute fatigue (Moss-Morris et al., 2011).  
The number of general somatic symptoms was also a risk factor for chronic fatigue in 
one of two studies (Wessely et al., 1995) and for CFS (Moss-Morris et al., 2011), but number 
of infection specific symptoms was not a risk factor for chronic fatigue (Wessely et al., 1995, 
Moss-Morris et al., 2011). 
High total number of symptoms was significantly related to long-term fatigue in the 
only study assessing this time-point (Candy et al., 2003).  
 
Pre-existing health issues 
 Petersen et al. (2006) reported that pre-infectious fatigue was associated with sub-acute 
fatigue. In terms of chronic fatigue, pre-morbid fatigue was a risk factor in a higher quality, 
large community study (Wessely et al., 1995) but not a smaller, primary-care study (Cope et 
al., 1994). More general, pre-existing (chronic) health problems were associated with both 
chronic fatigue (Löwe et al., 2014), and long-term fatigue (van Loenhout et al., 2015).  
 
 
 
Social factors 
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Adverse events 
Prior adverse events in the past year (e.g. parents divorcing or separating) were a risk 
factor for CFS in adolescents (Jason et al., 2014), but not for sub-acute, chronic or long-term 
fatigue after IM (Candy et al., 2003) or sub-acute fatigue after STEC infection (Löwe et al., 
2014) in adults.  
 
GP interactions 
Sick certification related to the acute infection was a risk factor for chronic fatigue 
(Cope et al., 1994) and CFS (Cope et al., 1996), as was uncertain diagnosis of viral illness 
(Cope et al., 1994).  
 
Behavioural factors 
  
All-or-nothing behaviour  
One study found all-or-nothing behaviour, i.e. pattern of over-activity followed by the 
need to rest up and recover at the time of acute infection, was a risk factor for both sub-acute 
fatigue and CFS (Moss-Morris et al., 2011).  
 
Limiting behaviour 
Bed-rest during the illness (i.e. number of days in bed) was a risk factor for sub-acute 
fatigue (White et al., 2001), whereas self-reported limiting behaviour (i.e. reduction or 
avoidance of activity) (Moss-Morris et al., 2011) and being off work for more than 10 days 
(Candy et al., 2003) were not. 
Bed-rest (White et al., 2001, Jason et al., 2014) and days off school (Jason et al., 2014) 
were risk factors for CFS but, once again, self-reported limiting behaviour and being off work 
were not associated with CFS (Moss-Morris et al., 2011) or chronic or long-term fatigue 
(Candy et al., 2003). 
 
Previous GP attendance  
The number of GP consultations in the year prior to illness was a risk factor for sub-
acute fatigue in one study broadly defining fatigue ‘in the year after onset’ (Petersen et al., 
2006) but not in another using a defined time-point of 2 months (White et al., 2001). Prior GP 
consultations were also a risk factor for CFS, but not chronic fatigue (White et al., 2001). 
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Functioning and fitness 
A few different operationalisations of functioning and fitness were investigated. 
Impaired general functioning and poor physical functioning in the month prior to and during 
infection, were risk factors for sub-acute fatigue (Candy et al., 2003). Conversely, better 
physical fitness at baseline (objectively measured using a step test) was associated with a 
reduced risk of sub-acute fatigue (White et al., 2001). 
Of these variables, only physical fitness was associated with reduced risk of chronic 
fatigue and CFS (White et al., 2001). School based functioning was not associated with CFS 
in adolescents (Jason et al., 2014). 
In the one study which looked at long-term fatigue, only impaired general functioning 
was a risk factor (Candy et al., 2003). 
 
Cognitive factors 
 
General individual differences  
Perceived stress  
Jason et al. (2014) found that perceived stress was related to CFS in adolescents but 
Moss-Morris et al. (2011) did not find the same relationship in adults. Both studies reported 
univariate analyses, investigated IM and were of good quality across each of the domains 
assessed.  
 
Negative perfectionism 
Moss-Morris et al. (2011) reported that ‘negative perfectionism’, i.e. striving to achieve 
high goals to avoid negative consequences (Slade and Owens, 1998), was a risk factor for CFS, 
but not sub-acute fatigue. 
 
Attributional style 
Somatising (attributing symptoms to physical illness) and absence of normalising 
(attributing symptoms externally to situational or environmental factors) were risk factors for 
chronic fatigue (Cope et al., 1994). A psychological attribution style (attributing symptoms 
internally to emotional distress) was a risk factor for both chronic fatigue (Cope et al., 1994) 
and CFS (Cope et al., 1996). 
 
 Neuroticism 
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Neuroticism (also conceptualised as self- or relative-rated emotionality (White et al., 
2001)) was not a risk factor for sub-acute fatigue (Hickie et al., 2006, White et al., 2001). It 
was related to chronic fatigue after STEC infection (Löwe et al., 2014) and CFS in an IM 
sample (White et al., 2001) but not a combined IM, Q-fever, RRV sample (Hickie et al., 2006). 
In the one study using a long-term fatigue follow-up, neuroticism was not associated with long-
term fatigue (Hickie et al., 2006).  
 
Illness specific perceptions  
Various dimensions of patients’ beliefs about their illness were investigated in two IM 
studies: identity beliefs (patients’ attribution of general somatic symptoms to their acute 
infection) (Moss-Morris et al., 2011), prolonged recovery beliefs, and perceiving more serious 
illness consequences were all risk factors for sub-acute fatigue (Moss-Morris et al., 2011, 
Candy et al., 2003). Low personal control beliefs were a risk factor for sub-acute fatigue in one 
of these two studies (Moss-Morris et al., 2011). Conversely, higher coherence (how much 
someone feels they understand their acute illness) significantly reduced the risk of sub-acute 
fatigue, effectively acting as a protective factor (Moss-Morris et al., 2011). Interestingly, no 
studies found attributing the illness to a virus was a risk factor. 
Of these illness beliefs, prolonged recovery beliefs remained a risk factor for chronic 
fatigue (Candy et al., 2003) and CFS (Moss-Morris et al., 2011). Believing the infection to 
have serious consequences was also still a risk for chronic fatigue (Candy et al., 2003) but not 
CFS (Moss-Morris et al., 2011). Moss Morris et al.’s (2011) study received a higher quality 
rating because of its larger sample size and fewer dropouts. Higher coherence was again 
protective in relation to CFS (Moss-Morris et al., 2011). 
None of the illness beliefs were risk factors of long-term fatigue in the one study with 
this follow-up time-point (Candy et al., 2003). 
 
 
 
 
 
Emotional factors 
 
Anxiety 
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Anxiety was investigated in two IM studies (White et al., 2001, Moss-Morris et al., 
2011). It was a risk factor for sub-acute fatigue in one of these (Moss-Morris et al., 2011). Both 
studies found anxiety to be a risk factor for CFS, but not chronic fatigue (Moss-Morris et al., 
2011, White et al., 2001). 
 
Depression 
Depression at baseline was investigated in the same two studies. Only one of these 
found it to be a risk for sub-acute fatigue and CFS (Moss-Morris et al., 2011), although White 
et al. (2001) reported it was a risk factor for chronic fatigue.  
 
Distress 
Five studies focused on psychological distress; either general or illness related (negative 
perceptions of the emotional impact of symptoms).  
General (Candy et al., 2003) and illness related (Moss-Morris et al., 2011) distress were 
both risk factors for sub-acute fatigue. General distress was also a risk factor for chronic fatigue 
(Cope et al., 1994, Wessely et al., 1995, Candy et al., 2003), but not CFS (Cope et al., 1996), 
although no data was provided to support the latter finding. Illness related distress was 
associated with CFS (Moss-Morris et al., 2011). 
 In the only study measuring long-term fatigue, general distress was not a risk factor 
(Candy et al., 2003).  
 
Psychiatric diagnosis  
Psychiatric diagnosis at the time of infection was not related to sub-acute fatigue 
(Hickie et al., 2006).  
In terms of CFS, psychiatric diagnosis was a risk factor in univariate analyses of an 
adolescent IM cohort (Jason et al., 2014) but not in multiple regression analyses of an adult, 
combined IM/Q-fever/RRV cohort (Hickie et al., 2006). Psychiatric diagnosis at time of 
infection was not associated with long-term fatigue (Hickie et al., 2006). 
 
 
 
Premorbid (pre-infection) distress 
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A large number of operationalisations of premorbid distress, including the presence of 
pre-morbid mood disorder, psychiatric disorder (interview and GP record of 
disorder/treatment) and emotional problems were measured in eight studies. 
Premorbid emotional risk factors for sub-acute fatigue were investigated by four studies 
(White et al., 2001, Candy et al., 2003, Hickie et al., 2006, Petersen et al., 2006). Of these, only 
one study (the weakest on the data collection quality domain) reported an association with sub-
acute fatigue (Petersen et al., 2006).  
In terms of chronic fatigue, only two of the 14 pre-morbid distress measures (across 
four studies) were risk factors: GP record of pre-morbid mood disorder (White et al., 2001) and 
psychological morbidity during community sampling (Wessley et al., 1995). 
In terms of CFS, five of the 11 investigated variables (across 3 studies) were shown to 
be risk factors, all in White et al.’s (2001) study.    
 Premorbid distress, conceptualised as ‘psychiatric history from case-notes’, was a risk 
factor for long-term fatigue in one study with a broad follow-up period of 6-24 months 
(mean=18) (Hotopf et al., 1996), whereas it was not a risk at 12 months in two studies, when 
conceptualised as previous psychiatric disorder (diagnostic interview) (Hickie et al., 2006) or 
emotional problems (questionnaire) (Candy et al., 2003). 
 
 
Discussion 
 
Risk factors of persistent fatigue after acute infection varied depending on follow-up 
time-point and fatigue outcome definition. Despite this heterogeneity, there were some patterns 
in the data where variables were either risks for fatigue across time-points and/or definitions, 
or multiple studies reported that a particular variable was a risk factor.  These factors are 
summarised in Figure 2. Across all infection types, ‘distress’ and ‘fatigue at time of infection’ 
were significant risk factors for chronic fatigue. Other variables were only significantly 
associated with persistent fatigue at certain time points, suggesting that the significance of 
some risk factors may differ across the trajectory of sub-acute, chronic and long term fatigue.  
Biological factors, including CD4, CD8 and aspartate transaminase biomarkers and a 
range of infectious symptoms, largely appeared to be significant risk factors for sub-acute 
rather than chronic fatigue. The increased percentage of activated CD4 and CD8 suggests an 
altered inflammatory response, whereby the immune system is chronically activated (Lorusso 
et al., 2009). Chronic activation may also produce more severe infectious symptoms. This is in 
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line with the findings that infectious symptoms such as lymphadonophathy, fatigue and pain 
were also risks for sub-acute fatigue.  
Risk factors for fatigue across multiple time-points were patients’ cognitive and 
behavioural responses to their illness and symptoms, tendency to report a wide range of somatic 
symptoms when acutely ill, distress at time of infection (both general and illness related), and 
fatigue (both pre-morbid and at time of acute infection). Physical fitness at baseline reduced 
risk of fatigue post-infection. Findings for premorbid psychiatric diagnosis were more mixed.  
There were more negative than positive results in this area, suggesting that whilst chronic 
fatigue is related to distress it is less likely to be a sequelae of a mental health disorder.  
Sick certification and longer bed-rest at the time of infection were also associated with 
chronic fatigue and/or CFS. These risks could represent more severe infection or inflammatory 
responses and general ill health. On the other hand, they may represent generalised illness 
worry, reflected in the cognitive behavioural risks for fatigue across the six-month trajectory. 
These include the tendency to attribute symptoms to either psychological or physical illness 
rather than normal events, and to view illness and symptoms as chronic, serious and difficult 
to understand. The key self-reported behavioural risk was a pattern of boom and bust (all-or-
nothing) whereby patients overdo things on days they feel better and then have prolonged 
periods of needing to rest up as a consequence (Surawy et al., 1995). Only one study included 
this behavioural variable, so conclusions must be tentatively drawn.  
Finally, although retrospective reporting suggests previous stressful events precede 
CFS (Hatcher & House, 2003, Nater et al., 2011), the prospective findings for the role of prior 
stressful or adverse events were mixed, with only one of three studies (focused on adolescents) 
showing a significant association with fatigue (Jason et al., 2014). It may be that an individual’s 
feelings of stress or distress or an accumulation of daily hassles and pressures (rather than the 
occurrence of specific stressful events) are risk factors for ongoing fatigue, i.e. the subjective 
experience of stress levels (Nater et al., 2011). One study found that high personal standards 
(negative perfectionism) was associated with CFS which is in line with subjective feelings of 
falling short of self-imposed standards (Moss-Morris et al., 2011).   
All the prospective studies reviewed investigated simple linear associations between 
these biopsychosocial factors and persistent post-infection fatigue. However, existing 
theoretical models of persistent physical symptoms propose predisposing, precipitating and 
perpetuating risk factors which interact to create a vicious cycle of physical symptom 
maintenance (Deary et al. 2007, Moss-Morris et al., 2012). Drawing from and incorporating 
these theories, we present a hypothetical model of fatigue which illustrates how the risks factors 
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identified in this review may interact to maintain a vicious cycle of fatigue after infection (see 
Figure 3).  
Pre-existing health issues and fatigue, lack of fitness and distress/stress may be 
predisposing factors for post-infectious fatigue. When individuals with one or more of these 
vulnerability factors are exposed to an infection this may precipitate a heightened immune 
response and more severe acute symptoms. In turn, this may result in increased bed-rest, sick 
certification and time off work (prolonged inactivity).  In response, people may push quickly 
to get back to previous levels of activity only to find this ‘boom’ behaviour produces further 
symptoms. If these symptoms are attributed to a psychological or physical illness, rather than 
normalising these in relation to pushing too hard after a time of bed-rest or severe symptoms, 
patients may develop a negative representation of symptoms.  The response may be to rest 
again (bust behaviour) rather than risk activity. This in turn produces more symptoms and an 
ongoing vicious cycle.  Future research exploring interactions between these factors is needed 
to validate this model.   
 
Insert Figure 3 here. 
 
 
Clinical Implications 
As prolonged bed-rest, sick certification and all-or-nothing behaviour are associated 
with persistent fatigue, careful guidance about gradual return to work and activity may be more 
useful than suggesting patients should rest (Candy et al., 2002). Reducing the chance of 
physical deconditioning is important given findings that individuals with IM in a constrained 
activity condition took significantly longer to recover than those whose activity was 
unrestricted (Dalrymple, 1964).  
The evidence of cognitive behavioural factors and poor illness coherence as risk factors 
of post-infectious fatigue illustrates the importance of providing clear, explanatory models to 
patients, including the fact that prolonged symptoms may not necessarily relate to the original 
infection. It also highlights the potential for simple behavioural interventions to enhance post-
infection recovery, as demonstrated by a small, pilot randomised control trial targeting gradual 
return to activity in IM patients (Candy et al., 2004).  
 
Strengths and limitations of the review 
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 By focusing on prospective studies, this review allows greater confidence in directional 
relationships and identifies findings that could be relevant for persistent fatigue prevention.  
Whilst some studies undertook analyses controlling for certain variables, others did not. 
Where possible we extracted results relevant to the simplest, uncontrolled data analyses to 
promote comparability and decrease heterogeneity across studies. However, as some did 
control for possible confounds, this may have led to mixed findings in some areas.  
Importantly, the proposed model is constrained by the findings reported. Conclusions 
cannot be drawn about factors which have not been measured. Similarly, we cannot conclude 
which risk factors are ‘most important’. We looked for consistency across studies and/or time-
points and highlighted these factors in Figure 2. However, the variety of individual factors 
included, and importantly their inclusion in only one or two studies, limits the weight that can 
be assigned to these findings. Thus, it is important to stress that Figure 2 should only be viewed 
as a summary of this review’s findings in parallel with tables 3-7, as opposed to a definite 
model of the perpetuation of chronic fatigue. Therefore, although potential risk factors for 
persistent post-infectious fatigue have been highlighted by this review, these associations 
require further replication to confirm their role, particularly as the heterogeneity amongst 
findings could be accounted for by multiple factors: sample characteristics, clinical 
characteristics, level of analysis or study quality. The extent of the involvement of these factors 
requires clarification. 
 
Future research 
Most prospective studies explored linear relationships between persistent fatigue and a 
few risk factors in a clinical population, without specifying a theoretical model. Few used 
community sampling and none explored the possible interaction between risk factors. Using a 
defined model to choose risks factors in future work, and doing so within a large longitudinal 
sampling frame, will help build knowledge of the complex interaction of factors likely to be 
associated with fatigue after infection. More consistent control of possible confounders (e.g. 
age and gender) across studies would also allow for more direct comparison between studies. 
Investigating the interaction with other physiological variables associated with chronic fatigue 
such as decreased cortisol secretion, postural orthostatic tachycardia and microbiome 
abnormalities may help elaborate the biological parameters underpinning persistent fatigue 
(Powell et al., 2013, Lewis et al., 2013, Giloteaux et al., 2016).   
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In conclusion, the evidence and model presented are dependent on studies’ focus and 
methodology. Caution is advised when drawing conclusions about risk factors measured by a 
small number of studies. Despite the heterogeneity, certain variables were shown to be 
significantly associated with persistent fatigue across multiple studies and/or across the six-
month fatigue trajectory, many of which encompassed aspects of patients’ responses to illness. 
These modifiable psychosocial risk factors lend themselves to future early interventions to 
manage sub-acute, post-infectious fatigue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure captions 
 
Figure 1: Flow diagram detailing study inclusion and exclusion. 
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Figure 2: A summary of the biopsychosocial variables shown to be potential risk factors for 
persistent post-infectious fatigue up to six months. 
*Note: Risk factors in bold are those factors that were associated with persistent fatigue 
across time-points in the six-month trajectory, or those which were duplicated across 
studies. Those not in bold were mixed findings. Such discrepancies could be explained 
by different infectious illnesses, study characteristics (e.g. sample size, sample 
population, quality), statistical analyses (e.g. univariate versus multivariate), measures 
used (e.g. self-report versus objective measures) or fatigue measurement factors (e.g. 
definition, time-point). Evidence for risk factors marked with  ~  was very variable.  
Figure 3: A hypothetical vicious cycle of interacting risk factors for fatigue.  
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Figure 1: Flow diagram detailing study inclusion and exclusion. 
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Figure 2: A summary of the biopsychosocial variables shown to be potential risk factors for 
persistent post-infectious fatigue up to six months. 
*Note: Risk factors in bold are those factors that were associated with persistent fatigue 
across time-points in the six-month trajectory, or those which were duplicated across 
studies. Those not in bold were mixed findings. Such discrepancies could be explained 
by different infectious illnesses, study characteristics (e.g. sample size, sample 
population, quality), statistical analyses (e.g. univariate versus multivariate), measures 
used (e.g. self-report versus objective measures) or fatigue measurement factors (e.g. 
definition, time-point). Evidence for risk factors marked with  ~  was very variable.  
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Figure 3: A hypothetical vicious cycle of interacting risk factors for fatigue.  
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PsycINFO  
exp Prospective Studies/ or prospective.mp. 
exp Longitudinal Studies/ or longitudinal.mp. 
risk factors.mp. or exp Risk Factors/ 
risk variables.mp. 
exp At Risk Populations/ or risk.mp. 
exp Prediction/ or predict$.mp. 
exp Cohort Analysis/ or cohort.mp. 
cohort study.mp. 
exp Followup Studies/ or follow up.mp. 
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("postviral" or "post-viral" or "post viral").mp. [mp=title, abstract, heading word, table 
of contents, key concepts, original title, tests & measures] 
("postinfect$" or "post-infect$" or "post infect$").mp. [mp=title, abstract, heading 
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Infectious Mononucleosis.mp. 
mononucleosis.mp. 
glandular fever.mp. 
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Ross River virus.mp. 
viral meningitis.mp. 
viral hepatitis.mp. 
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exp Fatigue/ or exp Chronic Fatigue Syndrome/ or fatigue.mp. 
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encephalomyelitis.mp. 
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persistent fatigue.mp. 
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exp prospective study/ or prospective.mp. 
exp longitudinal study/ or longitudinal.mp. 
risk factors.mp. or exp risk factor/ 
risk variables.mp. or exp risk/ 
exp high risk population/ or at risk populations.mp. 
exp cohort analysis/ or exp follow up/ or cohort.mp. 
cohort study.mp. 
exp prediction/ or predict$.mp. 
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name, keyword] 
("postinfect$" or "post-infect$" or "post infect$").mp. [mp=title, abstract, heading 
word, drug trade name, original title, device manufacturer, drug manufacturer, 
device trade name, keyword] 
Infectious Mononucleosis.mp. or exp mononucleosis/ 
exp infectious mononucleosis/ or mononucleosis.mp. 
glandular fever.mp. 
("epstein barr" or "epstein-barr" or "EBV").mp. [mp=title, abstract, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
Epstein Barr virus.mp. or exp Epstein Barr virus/ 
"Epstein barr viral disorder".mp. 
epstein barr virus infection.mp. or exp Epstein Barr virus infection/ 
("Q-fever" or "Q fever" or "Qfever").mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
Coxiella burnetii.mp. or exp Coxiella burnetii/ 
Q fever.mp. or exp Q fever/ 
Ross River virus.mp. or exp Ross River alpha virus/ 
viral meningitis.mp. 
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viral hepatitis.mp. 
10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 
exp postviral fatigue syndrome/ or exp fatigue/ or exp chronic fatigue syndrome/ or 
exp muscle fatigue/ 
mental fatigue.mp. 
chronic fatigue.mp. 
myalgic encephalomyelitis.mp. 
exp encephalomyelitis/ or encephalomyelitis.mp. 
prolonged fatigue.mp. 
persistent fatigue.mp. 
astheni$.mp. or exp asthenia/ 
(tired$ or exhaust$).mp. [mp=title, abstract, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, keyword] 
(weary or weariness or weakness).mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
((loss or lost or lack) adj2 energy).mp. [mp=title, abstract, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
(feeling adj2 (drained or sluggish or weak)).mp. [mp=title, abstract, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
(sleepy or sleepiness or drowsy or drowsiness).mp. [mp=title, abstract, heading word, 
drug trade name, original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
(apathy or apathetic or lassitude or lethargic or lethargy).mp. [mp=title, abstract, 
heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
exp convalescence/ or delayed recovery.mp. 
fail$ to recover.mp. 
26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 
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9 and 25 and 42 
 
Medline  
prospective.mp. or exp Prospective Studies/ 
longitudinal.mp. or exp Longitudinal Studies/ 
risk factors.mp. or exp Risk Factors/ 
risk variables.mp. 
predict$.mp. 
exp Cohort Studies/ or cohort.mp. 
cohort analysis.mp. 
at risk populations.mp. 
follow up.mp. 
risk.mp. or exp Risk/ 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 
("postviral" or "post-viral" or "post viral").mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
("postinfect$" or "post-infect$" or "post infect$").mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
Infectious Mononucleosis.mp. or exp Infectious Mononucleosis/ 
mononucleosis.mp. or exp Epstein-Barr Virus Infections/ 
glandular fever.mp. 
("epstein barr" or "epstein-barr" or "EBV").mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
Epstein Barr virus.mp. 
"Epstein barr viral disorder".mp. 
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("Q-fever" or "Q fever" or "Qfever").mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
Coxiella burnetii.mp. or exp Coxiella burnetii/ 
Ross River virus.mp. or exp Ross River virus/ 
viral meningitis.mp. or exp Meningitis, Viral/ 
exp Hepatitis, Viral, Human/ or viral hepatitis.mp. 
12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 
exp Fatigue/ or exp Muscle Fatigue/ or exp Mental Fatigue/ or exp Fatigue 
Syndrome, Chronic/ or fatigue.mp. 
"chronic fatigue".mp. 
myalgic encephalomyelitis.mp. 
exp Encephalomyelitis/ or encephalomyelitis.mp. 
prolonged fatigue.mp. 
persistent fatigue.mp. 
exp Asthenia/ or asthenia.mp. 
(tired$ or exhaust$).mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
(weary or weariness or weakness).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
((loss or lost or lack) adj2 energy).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
(feeling adj2 (drained or sluggish or weak)).mp. [mp=title, abstract, original 
title, name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
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(sleepy or sleepiness or drowsy or drowsiness).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
(apathy or apathetic or lassitude or lethargic or lethargy).mp. [mp=title, 
abstract, original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier] 
delayed recovery.mp. 
fail$ to recover.mp. 
"post viral fatigue syndrome".mp. 
convalesence.mp. 
26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 
or 40 or 41 or 42 
11 and 25 and 43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix B: Quality Assessment Tool 
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Effective Public Health Practice Project – modified from intervention to observation focussed 
A. SELECTION BIAS 
1. Are the individuals selected to participate in the study likely to be representative 
of the target population? 
a. Very likely 
b. Somewhat likely 
c. Not likely 
d. Can’t tell 
2. What percentage of selected individuals agreed to participate? 
a. 80-100% agreement 
b. 60-79% agreements 
c. Less than 60% agreement 
d. Not applicable 
e. Can’t tell 
3. Are the characteristics of the patients included in the study clearly described?  
In cohort studies and trials, inclusion and/or exclusion criteria should be given. 
In case-control studies, a case-definition and the source for controls should be 
given. 
a. Yes 
b. No 
4. Were there important differences between those who did and did not participate? 
a. Yes 
b. No 
c. Can’t tell 
(Examples of confounders: race, sex, marital status/family, age, SES (income or 
class), education, health status) 
 
B. STUDY DESIGN 
1. Indicate the study design. 
a.  Randomized controlled trial 
b. Controlled clinical trial 
c.  Cohort analytical (two group pre + post) 
d. Case-control 
e.  Cohort (one group pre + post – before and after) 
f.  Interrupted time series 
g. Other. Specify ................. 
h. Can’t tell 
2. Was exposure biologically verified? 
a. Yes 
b. No 
3. Was apriori/theoretical justification of predictors described, and then also mirrored in 
results section? 
a. Yes  
b. No 
c.  Can’t tell 
 
 
 
C. CONFOUNDERS 
1. Were there important differences between cases and non-cases when outcome was 
measured?  
a.  Yes  
b. No 
c.  Can’t tell 
Commented [k1]: Additional question. Taken from Q3 Downs & 
Black (1998) checklist. 
Commented [k2]: Duplicated and adapted from C Q1 - Were 
there important differences between groups prior to the 
intervention? 
Commented [k3]: B Q2 from EPHPP not applicable - Was the 
study described as randomised? 
Replaced based upon Newcastle Ottawa Cohort Scale – Selection Q3 
Commented [k4]: Additional question based upon 
recommendations from Candy et al. (2002) systematic review. 
Commented [k5]: Adapted from EHPHH C Q1. Original question: 
Were there important differences between groups prior to the 
intervention? 
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(Examples of confounders: race, sex, marital status/family, age, SES (income 
or class), education, health status, pre-intervention score on outcome measure) 
 
2. If yes, indicate the percentage of relevant confounders that were controlled (either in 
the design (e.g. stratification, matching) or analysis). 
a. 80-100% (most) 
b. 60-79% (some) 
c. Less than 0% (few or none) 
d. Can’t tell 
 
D. BLINDING 
1. Was (were) the outcome assessor(s) aware of the exposure status of participants? 
a.  Yes  
b. No 
c.  Can’t tell 
2. Were the study participants aware of the research question? 
a.  Yes  
b. No 
c.  Can’t tell 
 
E. DATA COLLECTION METHODS 
1. Were data collection tools shown to be valid? 
a.  Yes  
b. No 
c.  Can’t tell 
2. Were data collection tools shown to be reliable? 
a.  Yes  
b. No 
c.  Can’t tell 
3. Was fatigue measured as the primary outcome?  
a. Yes  
b. No 
c. Can’t tell 
4. Was the follow-up time period adequately explained? 
a. Yes ..................... 
b. No 
 
F. WITHDRAWALS AND DROPOUTS 
1. Were withdrawals and dropouts reported in terms of numbers and/or reasons per 
group? 
a.  Yes  
b. No 
c. Can’t tell 
d. Not Applicable (i.e. on time surveys or interviews) 
2. Indicate the percentage of participants completing the study (if the percentage differs 
by groups, record the lowest). 
a.  80-100% 
b. 60-79% 
c.  Less than 60% 
d. Can’t tell 
e.  Not Applicable (i.e. retrospective case-control) 
3. Were there important differences between completers and dropouts?  
d. Yes  
e.  No 
f.  Can’t tell 
Commented [k6]: Include patients themselves as self-report 
Commented [k7]: D Q1 from EHPHH (omitted: aware of ‘the 
intervention or’ exposure...) 
Commented [k8]: Additional Q – Focus of study. 
Commented [k9]: Additional question: based on Newcastle 
Ottawa Cohort Scale – Outcome Q2 
Commented [k10]: Additional question – investigate attrition 
bias 
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(Examples of confounders: race, sex, marital status/family, age, SES (income 
or class), education, health status, pre-intervention score on outcome measure) 
 
G. ANALYSES 
1. Are the statistical methods appropriate for the study design? 
a.  Yes  
b. No 
c.  Can’t tell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Commented [k11]: Section G: ‘Intervention Integrity’ from 
EHPHH not applicable so omitted. 
H Q1, Q2 and Q4 from EPHPP omitted as not relevant: 
1.Indicate the unit of allocation (circle one) : community, 
organisation/institution, practice/office, individual. 
2. Indicate the unit of analysis (circle one) : community, 
organisation/institution, practice/office, individual. 
4. Is the analysis performed by intervention allocation status 
(i.e. intention to treat) rather than the actual intervention 
received? 
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Appendix C: Study characteristics and significant statistical outcomes 
Study Infection Participants  
(N, % female, 
mean age, 
setting, country) 
Follow up 
% 
Design and  
Statistical 
method 
Analysed variables 
- prospective 
- measured in relation to fatigue 
outcome 
Fatigue 
outcome 
- method 
- measure 
Fatigue 
measureme
nt time 
points 
Significant statistical outcomes 
Candy et al. 
2003 
IM (positive IM 
serology) 
N = 71 
60% female 
Mean age = 22.9 
(s.d. = 8.2) 
Three 
haematology and 
two virology labs, 
six  general 
practices and a 
student healthcare 
centre. 
Country: UK  
 
3 months: 
69% 
6 months: 
87%  
12 
months: 
70% 
Prospective 
cohort  
 
Mann-
Whitney U-
test 
Univariate 
Logistic 
regression 
OR 
Risk factor variables: activated 
CD4 and CD8 cytotoxic T cells, 
cortisol concentration, cortisol 
concentration change baseline -
6 months, more than one recent 
adverse life event, childhood 
experience of illness in family, 
past history of emotional 
problems, doing regular sport, 
10+ days off sick, 'recovered' at 
interview, given advice to rest 
by GP, high total symptom, 
high symptoms severity, low 
physical functioning, poor 
physical functioning in last 
month, poor emotional 
functioning in last month, poor 
functioning on Work and Social 
Adjustment Scale (WSAS), 
GHQ-12>5 (psychological 
distress), low control/cure 
(IPQ), high consequences 
(IPQ), expect recovery will take 
>1 month. 
Questionnaire 
Chalder Fatigue 
Scale 
baseline,  
3 months, 
6 months, 
12 months 
Fatigue at 3 months was associated with higher acute 
phase % of activated CD4 (U=5.0, p=.02) and 
activated CD8 (U=7.0, p=0.039).  
All the following are significant at p<.05: 
Fatigue at 3 months was also associated with high 
total symptom (OR 8.6, 95% CI 2.0-37), high 
symptom severity (OR 12, 95% CI 2.8-52), low 
physical functioning (OR 4.5, 95% CI 1.3-15), poor 
physical functioning in last month (OR 6.7, 95% CI 
1.6-28), poor functioning on WSAS (OR 20, 95% CI 
3.8-1.4 [sic]), GHQ-12>5 (OR 11, 95% CI 2.7-42), 
high consequences (OR 5.8, 95%CI 1.6-20) and 
expect recovery will take >1 month (OR 8.4, 95% CI 
2.0-36). 
Fatigue at 6 months was associated with GHQ-12>5 
(OR 2.8, 95% CI 1.0-8.1), high consequences (OR 
3.0, 95% CI 1.0-9.0) and expect recovery will take >1 
month (OR 3.4, 95% CI 1.1-11). 
Fatigue at 12 months was associated with high total 
symptom (OR 5.7, 95% CI 1.4-24) and poor 
functioning on WSAS (OR 6.5, 95% CI 1.5-27). 
Cope et al. 
1994 
'viral illness' 
(diagnosis) 
N = 618 
63.5% female 
Mean age  
Male = 29.20 
(s.d.= 7.7) 
Female = 30.15 
(s.d.= 7.7) 
Setting: 42 
general practices 
Country: UK 
81.20% Prospective 
cohort 
 
t-test 
Logistic 
regression 
OR 
Risk factor variables: GP sick 
note, GP diagnosis, medication, 
previral fatigue, symptoms, 
virus beliefs, GHQ-3 score 
(psychological distress), 
attributional style 
(psychologising, somatising, 
normalising) 
Questionnaire 
Fatigue 
Questionnaire  
(David et al., 
1990) 
6 months  Fatigue at 6 months was associated with receiving a 
sick note during infection (OR 1.68, 95% CI 1.05-
1.54, p=.01), less certain diagnosis of viral illness 
(X2=19.26, p=.02), GHQ-3 scores at initial 
presentation (p=.004), higher psychologising 
attribution scores (p<.05), higher somatising 
attribution scores (p<.05), lower normalising 
attribution scores (p<.05), belief that catch virus 
when rundown or under stress (sub-scale) (t=3.02, 
p=.003). 
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Cope et al. 
1996 
'viral illness' 
(diagnosis) 
N = 128, 
Cases N=64, 78% 
female, mean age 
= 30.5 (s.d. = 6.5) 
Controls N = 64, 
78% female, 
mean age = 31.4 
(s.d. = 7.3) 
Setting: General 
practice 
Country: UK 
78% Prospective 
cohort 
(case-
control) 
 
Logistic 
regression 
OR 
Risk factor variables: GHQ-3 
score (psychiatric morbidity), 
attributional style, sick 
certification, presence of fatigue 
(at time of viral illness), past 
psychiatric history (verified by 
GP records). 
Interview 
CFS  
(Oxford criteria) 
6 months CFS at 6 months was associated with sick 
certification (p=.002, OR 8.5, CI 4.2-17.2), a 
psychological symptom attributional style (p=.007, 
OR 2.1, CI 1.6-2.7) and presence of fatigue at time of 
viral illness (p=.05, OR 6.4, CI 2.5-16.4). 
Hickie et al. 
2006 
 
 
EBV, Q fever, 
RRV (positive 
serology tests) 
N = 253 
43% female 
Mean age = 34 
(16-77) 
Setting: Family 
practitioner 
practices, four 
diagnostic 
pathology 
laboratories 
Country: 
Australia 
90.5% Prospective 
cohort  
 
 
Stepwise 
multiple 
regression - 
standardised 
beta co-
efficient 
Risk factor variables: acute 
sickness, irritability, 
musculoskeletal pain, mood 
disturbance, neurocognitive 
disturbance, fatigue, premorbid 
psychiatric disorder, 
intercurrent psychiatric 
disorder, neuroticism score, 
locus of control score 
Questionnaire 
SOMA subscale 
of SPHERE  
 
Interview 
CFS  
(CDC criteria) 
3 months, 6 
months, 12 
months 
Fatigue at 3 months was associated with irritability 
(b=0.24, p<.05), musculoskeletal pain (b=0.27, 
p<.05), neurocognitive disturbance (b=0.24, p<.05) 
and fatigue (b=0.50, p<.001). 
CFS at 6 months was associated with musculoskeletal 
pain (b= 0.30, p<.05) and fatigue at baseline (b= 0.35, 
p<.001).  
CFS at 12 months was associated with fatigue at 
baseline (b= 0.27, p<.05) 
Hotopf et al. 
1996 
 
 
 
 
 
 
 
 
 
 
acute onset viral 
meningitis 
(clinical 
diagnosis) 
 
(controls - other 
viral diagnoses) 
N = 159 (83 
patients, 76 
controls) 
Cases 64% female 
Controls 46% 
female 
Mean ages: 32 
and 31 
Setting: Four 
virology 
laboratories and 
specialist 
hospitals. 
Country: UK (?) 
 
 
Prospective 
case-control 
 
Logistic 
regression 
OR 
(adjusted) 
Risk factor variables: 
psychiatric history 
Questionnaire 
Chalder Fatigue 
Scale 
CFS  
(Oxford criteria, 
CDC criteria) 
6-24 months 
post onset 
(mean = 18 
months) 
Psychiatric history was a risk factor for  CFS (Oxford 
criteria) (OR 3.58, 95% CI 1.2-10.6, p=.02) and CFS 
(CDC criteria) (OR 7.82, 95% 1.8-34.3, p=.006), but 
not chronic fatigue (as measured on the Chalder 
Fatigue Scale) (OR = 1.33, 95% CI 0.5-3.4, p=.55). 
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Huang et al. 
2010 
 
 
IM (positive 
monospot lab 
records) 
N = 301 
CFS N=39, 89.7% 
female 
Controls N=39 
'adolescents' 
Setting: clinical 
care sources e.g. 
school clinics, 
paediatric 
practices, virology 
lab of hospital. 
Country: USA 
 
Same cohort as 
Katz et al. (2009) 
 Prospective 
cohort 
(case-
control) 
 
t-test 
Compare 
CFS cases v 
controls 
 
 
 
 
 
 
 
 
Risk factor variables: 
(measured for 'before' and 
'during mono'): Physical 
Activity: 20-Minute hard 
exercise, 20-Minute light 
exercise, 
Television/video/computer, 
Sleep, Napping, Other sedentary 
activity. 
Fatigue severity at baseline. 
Interview 
CFS  
(CDC criteria - 
revised by Jason 
et al. 2006) 
6 months 
 
CFS at 6 months was associated with fatigue severity 
at baseline, t(39)=3.70, p<.001. 
Jason et al. 
2014 
 
 
IM (positive 
monospot test) 
N = 301  
CFS: N = 39, 
89.7% female, 
mean age = 16.09 
(1.4), 87.2% 
Caucasian 
Controls: N = 50, 
74% female, 
mean age = 16.1 
(1.5), 94% 
Caucasian 
Setting: clinical 
care sources e.g. 
school-based 
health clinics.  
Country: USA 
 
Same cohort as 
Katz et al. (2009) 
53 of 70 
'not 
recovered'
=75.7% 
 
39/53 
classified 
as CFS. 
Prospective 
cohort 
 (case-
control) 
 
Logistic 
regression 
b, Wald X2, 
OR. 
Risk factor variables: autonomic 
symptoms, perceived stress 
score, life events score, family 
stress (around or prior to mono 
onset?, continuing?, since mono 
any family stress?, continuing?), 
days spent in bed, days of 
school missed, hard time 
attending school regularly?, 
difficulties with concentrating, 
learning or remembering, at 
least one current psychiatric 
diagnosis, total number of 
current diagnoses received. 
Interview 
CFS 
(Jason et al. 
(2006) revision 
of the CDC 
criteria) 
6 months  CFS at 6 months was associated with autonomic 
symptoms (b=.14, X2=22.23, OR 1.15, p<.001), 
perceived stress (b=.10, X2=9.81, OR 1.10, p<.001), 
life events (b=.60, X2=13.14, OR 1.83, p<.001), days 
spent in bed (b=.08, X2==5.98, OR 1.08, p=.01), days 
of school missed (b=.09, X2=5.89, OR 1.09, p=.01), 
at least one current psychiatric diagnosis (b=1.39, 
X2=9.28, OR 4.00, p<.001) and total number of 
current diagnoses received (b=.68, X2=5.13, OR 1.97, 
p=.02). 
46 
 
Katz et al. 
2009 
 
 
IM (positive 
monospot test) 
N = 301 
CFS N=39, 90% 
female 
Controls N=50 
'adolescents' 
Setting: clinical 
care sources e.g. 
school clinics, 
pediatric 
practices, virology 
lab of hospital. 
Country: USA 
 
53 of 70 
'not 
recovered'
=75.7% 
 
39/53 
classified 
as CFS.  
Prospective 
cohort 
(case-
control) 
 
Fisher's 
exact test 
X2 
Risk factor variable: prescribed 
steroid treatment during acute 
episode of mononucleosis. 
Interview 
CFS  
(CDC criteria - 
revised by Jason 
et al., 2006) 
 
(Questionnaire 
Chalder Fatigue 
Scale) 
6 months, 
12 months, 
24 months 
none 
Kremers et al. 
2014 
Q-fever 
(positive 
serology) 
N = 102 
35.3% female 
Mean age = 48 
(s.d. = 16) 
Setting: 
Microbiology & 
Infection Control 
Hospital 
Department.  
Country: 
Netherlands 
70.70% Prospective 
cohort 
 
Mann 
Whitney U 
test 
Risk factor variables: 
interleukin-6 and C-reactive 
protein levels. 
Questionnaire 
Nijmegen 
Clinical 
Screening 
Instrument: 
fatigue sub-
domain 
4 years after 
diagnosis 
none. 
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Löwe et al. 
2014 
Shiga Toxin-
Producing 
Escherichia coli 
0104 (STEC) 
(clinical 
diagnosis) 
N = 389 
69% female 
Mean age = 46 
(s.d. = 17) 
Setting: 13 
hospitals 
Country: 
Germany 
79% Prospective 
cohort 
 
Multiple 
linear 
regression  
Risk factor variables: prior 
psychiatric disorder, prior 
traumatic event, diarrhoea in the 
past 4 months, pre-existing 
chronic condition (e.g. IBS, 
fibromyalgia), neuroticism, 
pessimism, optimism, self-
efficacy, duration of in-patient 
treatment (weeks), treatment in 
intensive care unit, haemolytic 
uremic syndrome, neurological 
symptoms, more than 4 
instances of diarrhoea on 3 or 
more days, abdominal pain, 
length of bloody diarrhoea, 
fever, fear of death, social 
support. 
Questionnaire 
Chalder Fatigue 
Scale (validated 
German 
version) (Martin 
et al., 2010) 
6 months 
("fatigue 
persisting 
for 3 or 
more 
consecutive 
months"). 
Fatigue at 6 months was associated with pre-existing 
chronic condition (b = 1.75, 95% CI 0.43-3.07, 
p=.009), neuroticism (b = 1.22, 95% CI 0.20-2.23, 
p=.019) and treatment in intensive care unit (b = 1.73, 
95% CI 0.03-3.43, p=.046). 
Moss-Morris 
et al. 2011 
Glandular fever 
(GF) (positive 
monospot or 
serology test) 
N = 246 
62% female 
Mean age = 22.8 
(s.d. = 8.3) 
96% NZ 
European, 2% 
Asian, 2% Maori 
Setting: 
community 
clinical diagnostic 
service. 
Country: New 
Zealand 
91%  - 3 
months 
88% - 6 
months 
Prospective 
cohort 
(case-
control) 
 
Independent 
sample t-
tests and X2 
tests. 
Individual 
logistic 
regression 
OR. 
Risk factor variables: mean GF 
symptoms, mean non-GF 
symptoms, doctor's advice to 
rest, doctor's advice to avoid 
exercise, doctor's advice to take 
medication, perceived stress, 
negative perfectionism, anxiety, 
depression, illness identity, 
timeline, consequences, 
personal control, illness 
coherence, emotional 
representations, all-or-nothing 
behaviour, limiting behaviour. 
Questionnaire 
CFS  
(CDC or Oxford 
criteria) 
3 months 
6 months 
Fatigue at 3 months was associated with non-GF 
somatic symptoms (t(222) = -4.51, p<.001), anxiety 
(OR 1.22, 95% CI 1.08-1.38, p=.002), depression 
(OR 1.26, 95% CI 1.09-1.46, p=.002), illness identity 
(OR 1.17, 95% CI 1.01-1.35, p=.03), timeline (OR 
1.3, 95% CI 1.09-1.54, p=.004), consequences (OR 
1.15, 95% CI 1.02-1.29, p=.03), personal control (OR 
0.86, 95% CI 0.75-0.98, p=.02), illness coherence 
(OR 0.75, 95% CI 0.62-0.92, p=.01), emotional 
representations (OR 1.17, 95% CI 1.06-1.29, p=.002), 
all-or-nothing behaviour (OR 1.13, 95% CI 1.03-
1.24, p=.01). 
CFS at 6 months was associated with non GF somatic 
symptoms (t(215) = -2.19, p=.03), negative 
perfectionism (OR 1.08, 95% CI 1.01-1.16, p=.04), 
anxiety (OR 1.18, 95% CI 1.03-1.34, p =.02), 
depression (OR 1.26, 95% CI 1.06-1.50, p=.01), 
timeline (OR 1.38, 95% CI 1.11-1.72, p=.004), illness 
coherence (OR 0.77, 95% 0.62-0.95, p=.01), 
emotional representations (OR 1.11, 95% CI 1.00-
1.24, p=.05), all-or-nothing behaviour (OR 1.14, 95% 
CI 1.02-1.26, p=.02). 
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Petersen et al., 
2006 
 
 
IM (positive 
antibody test) 
 
(2 comparative 
cohorts - 
influenza and 
tonsillitis) 
N=1438 (1318 not 
including pre-
morbid fatigue). 
Median age = 19 
years 
Setting: General 
practices (General 
Practice Research 
Database). 
Country: UK 
n/a Prospective 
cohort  
(matched, 
historic) 
 
Univariate 
regression 
OR 
Multivariabl
e logistic 
regression 
Risk factor variables: 
lymphadenopathy within 2 
months of positive test, number 
of GP consultations in year 
before onset, number of 
sickness certificates in the year 
before onset, premorbid anxiety 
or depressive (mood) disorder, 
premorbid fatigue, premorbid 
atopy (eczema, asthma or hay 
fever). 
Database codes: 
Fatigue 
symptoms and 
diagnoses 
Fatigue: in 
year after 
onset 
(median = 
55 days) 
Fatigue after IM was associated with premorbid 
fatigue (OR 2.0, 95% CI 1.2-3.1, p=.004), 3+ GP 
consultations in the year before IM (OR 1.7, 95% CI 
1.2-2.3, p=.002) and premorbid mood disorder (OR 
2.6, 95% CI 1.4-4.8, p=.002). 
Schur et al. 
2007 
IM (positive 
monospot test) 
N = 150 
53% female 
Mean age = 21.3 
(s.d. = 6.7) 
90% Caucasian 
Setting: Health 
maintenance 
organisation.  
Country: USA 
95% Prospective 
cohort 
 
Logistic 
Regression 
OR 
(unadjusted 
and 
adjusted) 
Risk factor variables: BMI at 
baseline, weight change from 
baseline to 6 months 
Questionnaire 
4-item vitality 
subscale of 
Medical 
Outcomes SF-
36 health survey 
baseline, 6 
months  
none 
Seet et al. 
2007 
Dengue 
infection 
(serologically 
confirmed) 
N = 127  
44.1% female 
Mean age=36.06 
(s.d.=13.722) 
75.6% Chinese, 
17.3% Malay, 
4.7% Indian 
Setting: Hospital 
Country: 
Singapore 
100% Prospective 
cohort 
 
Multivariate 
logistic 
regression 
OR 
Risk factor variables:  
Symptoms: fever, nausea, chills, 
poor appetite, fatigue, cough, 
abdominal pain, vomiting, 
diarrhoea, rashes, muscle pain, 
headaches.  
Laboratory parameters: 
(concentrations of…) White cell 
count, haemoglobin, 
haematocrit, platelet, sodium, 
potassium, urea, creatinine, 
albumin, total bilirubin, 
aspartate transaminase, alkaline 
transaminase, alkaline 
phosphatase, lactate 
dehydrogenase. Prothrombin 
time, activated thromboplastin 
time. 
Dengue severity (dengue 
haemorrhagic fever) 
Questionnaire  
Chalder Fatigue 
Scale 
2 months 
following 
hospitalisati
on 
Fatigue 2 months after infection was associated with: 
presence of chills (OR 6.904, 95% CI 1.157-41.202, 
p=.034) and absence of rashes (OR 0.113 95% CI 
0.017-0.774, p=.026). 
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van Loenhout 
et al. 2015 
Q-fever 'lab 
confirmed' 
N = 336 
48.5 % female 
Mean age = 48.5 
(s.d. = 13.9) 
98.5 % Dutch 
Setting: 
Municipal Health 
Services 
Country: 
Netherlands 
82.74% Prospective 
cohort 
 
Multivariate 
regression 
Risk factor variables: pre-
existing health problems, 
diagnosis during the acute Q-
fever episode. 
Questionnaire 
Nijmegen 
Clinical 
Screening 
Instrument: 
fatigue sub-
domain 
12 and 24 
months 
Pre-existing health problems were associated with 
fatigue at 12 months, b = 4.45, CI 0.79 - 8.10, 
p=.017, and 24 months, b = 7.41, CI 3.65 - 11.17, 
p<.001. 
Wessley et al. 
1995 
 
 
General 
infections 
 N=1167 of 1199 
exposed, 68% 
female, mean age 
= 32.7 (s.d.=7.5)  
N=671 from 
exposed cohort 
with complete 
data from all 
stages. 
Setting: 
Community 
sampling. General 
practices 
Country: UK 
 
84% Prospective 
cohort  
(cohort and 
case-
control) 
 
 
X2 
Independent 
regression 
OR 
Risk factor variables: pre-onset 
fatigue, pre-onset psychological 
distress, psychological distress 
at time of infection, belief that 
fatigue at presentation was due 
to a physical cause, viral 
symptoms, local symptoms. 
Questionnaire 
Fatigue Scale 
(Chalder) 
Community 
screening, 
baseline, 6 
months  
Fatigue at 6 months was associated with premorbid 
fatigue (OR 3.0, 95% 1.9-4.7, p<.001), pre-onset 
psychological morbidity (OR 1.8, 95% CI 1.2-2.9, 
p=.009), psychological morbidity at time of infection 
(OR 1.8, 95 CI, p=.01) and higher number of general 
viral symptoms (no data).   
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White et al. 
2001 
IM (positive 
monospot and 
10%+ atypical 
lymphocytes) 
and non-IM 
(other 
diagnosed 
infections)  
 
(upper 
respiratory tract 
infection 
comparison 
group) 
N = 250 (118 IM, 
127 non-IM, 5 
excluded) 
51% female 
Setting: City 
University, 
London. 
St Bartholomew's 
Hospital, London 
General surgeries 
Country: UK 
 
Prospective 
cohort 
 
Stepwise 
logistic 
regression; 
Univariate 
Relative 
Risk 
Risk factor variables: cervical 
lymphadenopathy, atopy, AST 
at 1 month, yGT at 1 month, 
bilirubin at 1 month, fatigue at 
onset, time in bed at onset, 
exercise power, fitness, GP 
attendance in year before onset, 
premorbid psychiatric disorder 
(PPD) at any time, PPD in year 
before onset, PPD in 2 weeks 
before onset, GP record of PPD, 
GP record of any PPD 
treatment, premorbid mood 
disorder (PMD) at any time, 
PMD in year before onset, PMD 
in 2 weeks before onset, GP 
record of PMD, depression at 1 
month, anxiety at 1 month, self-
rated extroversion, relative rated 
extroversion, self-rated 
emotionality, relative-rated 
emotionality 
Interview 
Empirically 
defined fatigue 
syndrome 
(White et al., 
1995). 
CFS:  
Oxford criteria 
CDC criteria 
1, 2, 6 
months after 
symptom 
onset. 
Primary 
care records 
examined 
2.5 years 
later. 
Fatigue at 2 months was associated with cervical 
lymphadenopathy (RR 4.9, CI 2.5-9.7), AST at 1 
month (RR 2.4, 95% CI 1.3-4.5), fatigue at onset (RR 
2.0, 95% CI 1.3-3.0), time in bed at onset (RR 2.0, 
95% CI 1.2-3.2), lower fitness (RR 0.6, 95% CI 0.4-
1.0). 
Fatigue at 6 months was associated with AST at 1 
month (RR 2.3, 95% CI 1.0-4.8), fatigue at onset (RR 
2.1, 95% CI 1.0-4.3), lower fitness (RR 0.4, 95% CI 
0.2-0.9), GP record of PMD (RR 2.1, 95% CI 1.0-
4.4), depression score (RR 2.1, 95% CI 1.0-4.5). 
CFS (Oxford criteria) at 6 months was associated 
with time in bed at onset (RR 3.2, 95% CI 1.5-7.1), 
lower fitness (RR 0.4, 95% CI 0.2-0.9), GP 
attendance in year before onset (RR 4.1, 95% CI 1.7-
10.3), GP record of PPD (RR 4.0, 95% CI 2.2-7.4), 
GP record of any PPD treatment (RR 3.7, 95% CI 
2.0-6.8), PMD at any time (RR 2.1, 95% CI 1.2-3.8), 
PMD in 2 weeks before onset (RR 2.9, 95% CI 1.5-
5.6), GP record of PMD (RR 3.5, 95% CI 2.0-6.3), 
anxiety score (RR 3.9, 95% CI 1.4-11.0), mood 
disorder at 2 months (RR 4.4, 95% CI 2.6-7.5), self-
rated emotionality (RR 1.9, 95% CI 1.0-3.5, p<.05), 
relative-rated emotionality (RR 2.3, 95% CI 1.2-4.2). 
CFS (CDC criteria) at 6 months was associated with 
time in bed at onset (RR 2.2, 95% CI 1.1-4.6), lower 
fitness (RR 0.5, 95% CI 0.2-1.0), GP attendance in 
year before (RR 3.0, 95% CI 1.3-7.0), GP record of 
PPD (RR 2.3, 95% CI 1.2-4.6), PMD at any time (RR 
2.2, 95% CI 1.2-3.9), PMD in 2 weeks before onset 
(RR 2.8, 95% CI 1.4-5.8). 
 
p<.05 for all. 
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Table 3: Summary of biological factors shown to be significantly associated with the development of persistent fatigue at at least one time-point.  
 
  Biological 
   
     
    Haematological 
& biochemical 
parametres 
 
Individual 
symptoms 
during acute 
illness 
 
Number of 
acute 
symptoms 
 Severity of 
acute 
symptoms 
Pre-existing 
health issues 
 
 
   
CD4/CD8 
 
AST 
 
Fatigue 
Other 
individual 
symptoms 
 
General 
 
Illness 
specific 
 
 
Fatigue 
 
General 
health  
  
    
  
 
  
Total number 
of studies 
  1 2 5 9 3 2 4 3 2 
Sub-acute   1/1 1/2 2/3 mixed* 2/2 0/1 1/2 1/1*  
6 months chronic 0/1 1/1 1/1 mixed 1/2 0/1 1/3 1/2 1/1 
 
CFS 
(any 
diagnost
ic 
criteria) 
 
0/1 3/4 mixed 1/1 0/1 
 
  
Long term   
  
1/1 mixed 1/1  1/1  1/1 
 
*Includes Petersen et al. (2006). Fatigue measured in ‘year after onset’ through database search of diagnoses and symptoms. Median = 55 days, therefore, 
included as sub-acute. 
Note: In this table, and the following ones, the ratios denote the number of papers which report each respective risk factor as significant, out of the number of 
papers which investigated it as a risk factor.
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Table 4: Summary of social factors shown to be significantly associated with the development of persistent fatigue at at least one time-point. 
 
  Social 
 
  
    Adverse 
events 
GP interactions   
 
  
 
sick note uncertain 
diagnosis 
Total number of 
studies 
  3 2 1 
Sub-acute   0/1 
  
6 months chronic 0/2 1/1 1/1 
 
CFS (any 
diagnostic 
criteria) 
1/1 1/1  
 
 
Long term   0/1 
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Table 5: Summary of behavioural factors shown to be significantly associated with the development of persistent fatigue at at least one time-point. 
 
  Behaviour 
  
   
    All-or-
nothing 
behaviour 
Limiting 
behaviour 
 
Previous GP 
attendance 
General 
 functioning 
(reduced) 
Physical 
functioning/fitness 
(reduced) 
 
  
 
 
Other 
 
Bed-rest 
 
 
 
 
  
    
 
 
Total number of 
studies 
  1 3 2 2 2 2 
Sub-acute   1/1 0/2 1/1 1/2* 1/1 2/2 
6 months chronic 
 
0/1 0/1 0/1 0/1 1/2 
 
CFS (any 
diagnostic 
criteria) 
1/1 1/2 2/2 1/1 0/1 1/1 
Long term   
 
0/1 
  
1/1 0/1 
 
*Includes Petersen et al. (2006). Fatigue measured in ‘year after onset’ through database search of diagnoses and symptoms. Median = 55 days, therefore, 
included as sub-acute. 
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Table 6: Summary of cognitive factors shown to be significantly associated with the development of persistent fatigue at at least one time-point. 
   Cognitive 
         
    Individual 
traits 
      Illness specific perceptions 
    
Neuroticism 
 
Negative 
perfectionism 
 
Perceived 
stress 
 
Attributional 
style 
 
Identity 
 
Timeline 
 
Consequences 
 
Control 
 
Illness 
coherence 
(low) 
   
         
Total number 
of studies 
  3 1 2 2 1 2 2 2 1 
Sub-acute   0/2 0/1 0/1 
 
1/1 2/2 2/2 1/2 1/1 
6 months chronic 1/2 
  
1/1 
 
1/1 1/1 0/1 
 
 CFS (any 
diagnostic 
criteria) 
1/2 1/1 1/2 1/1 0/1 1/1 0/1 0/1 1/1 
Long term   0/1 
    
0/1 0/1 0/1 
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Table 7: Summary of emotional factors shown to be significantly associated with the development of persistent fatigue at at least one time-point. 
 
  Emotional 
    
  
    Anxiety Depression Distress 
 
Psychiatric 
diagnoses 
Pre-morbid (pre-infection) distress 
 
  
  
General Illness 
related 
  
 
  
      
Total number of 
studies 
  2 2 4 1 2 8 
Sub-acute   1/2 1/2 1/1 1/1 0/2 1/4* 
6 months chronic 0/1 1/1 3/3 
  
2/4 
 
CFS (any 
diagnostic 
criteria) 
2/2 1/2 0/1 1/1 1/2 1/3 
Long term   
  
0/1 
 
0/1 1/3** 
 
*Includes Petersen et al. (2006). Fatigue measured in ‘year after onset’ through database search of diagnoses and symptoms. Median = 55 days, therefore, 
included as sub-acute. 
**Includes Hotopf et al. (1996). Fatigue time-point was 6-24 months. Mean = 18 months, therefore, included as long term. 
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Table 8: Summary of ratings for each study across the quality domains 
 Selection 
Bias 
Study 
Design 
Confounders Blinding Data 
Collection 
Withdrawals/
Dropouts  
(participant 
follow-up) 
Overall rating 
Candy et al. (2003) 2/3 1 2 2 1 2 2 moderate 
Cope et al. (1994) 1/2 3 2 2 2 1 2 moderate 
Cope et al. (1996) 2 3 1 2 2 2 2 moderate 
Hickie et al. (2006) 2/3 2 1 2 1 3 2 moderate 
Hotopf et al. (1996) 2 2 1 2 3 2 2 moderate 
Haung et al. (2010) 
Referenced Katz et al. for study 
details 
2 2 1 1 1 3 1/2 
strong-
moderate 
Jason et al. (2014) 2 2 2 1 1 2 2 moderate 
Katz et al. (2009) 2 2 3 1 2 2 2 moderate 
Kremers et al. (2014)         
Loewe et al. (2014) 2 2 3 2 1 2 2 moderate 
Moss-Morris et al. (2011) 2/3 1 1 2 1 1 1/2 strong-
moderate 
Peterson et al. (2006) 1 2 1 2 3 2 2 moderate 
Schur et al. (2007) 2/3 2 1 2 2 3 2 moderate 
Seet et al. (2007) 3 2 3 2 2 1 2/3 
moderate-
weak 
van Loenhout et al. (2015) 1 2 3 2 2 1 2 moderate 
Wessely et al. (1995) 2 3 1 2 1 1 1/2 
strong-
moderate 
White et al. (2001) 2/3 2 1 1 2 2 2 moderate 
Key: 1= strong, 2= moderate, 3= weak 
 
